Table 5 Summary of differentially expressed genes between T135 and U135 using IPA
Top Bio Functions | Â | Â |
|---|---|---|
Diseases and Disorders | Â | Â |
Name | p-value1 | Molecules2 |
Cancer 4 | 9.23E-06-2.87E-02 | 7 |
Reproductive System Disease 4 | 9.23E-06-6.44E-03 | 7 |
Genetic Disorder | 3.22E-03-2.87E-02 | 5 |
Immunological Disease | 3.22E-03-3.22E-03 | 1 |
Infection Mechanism | 3.22E-03-4.11E-02 | 4 |
Molecular and Cellular Functions | Â | Â |
Name | p-value | Molecules |
Cell Cycle | 5.50E-04-2.87E-02 | 3 |
Cell Death | 1.04E-03-2.43E-02 | 8 |
Cell-To-Cell Signaling and Interaction | 3.22E-03-4.42E-02 | 5 |
Cellular Assembly and Organization | 3.22E-03-4.42E-02 | 7 |
Cellular Compromise | 3.22E-03-4.42E-02 | 3 |
Physiological System Development and Function | Â | Â |
Name | p-value | Molecules |
Embryonic Development | 5.50E-04-2.55E-02 | 5 |
Tissue Development | 5.50E-04-4.11E-02 | 7 |
Hematological System Development and Function | 2.47E-03-4.42E-02 | 7 |
Cell-mediated Immune Response | 3.22E-03-4.42E-02 | 2 |
Nervous System Development and Function | 3.22E-03-6.44E-03 | 2 |
Top Canonical Pathways | Â | Â |
Name | p-value | Ratio 3 |
LPS/IL-1-mediated Inhibition of RXR Function | 3.61E-03 | 4/216 (0.019) |
Histidine Metabolism | 1.26E-02 | 2/120 (0.017) |
PXR/RXR Activation | 2.2E-02 | 2/91 (0.022) |
Arginine and Proline Metabolism | 2.68E-02 | 2/183 (0.011) |
Glycerolipid Metabolism | 4.51E-02 | 2/156 (0.013) |